Targeting ROR1 in combination with pemetrexed in malignant mesothelioma cells

Although malignant mesothelioma (MM) is rare among thoracic malignancies, approximately 1500 and 3000 patients are newly diagnosed each year in Japan and the United States [1], respectively. Treatment of MM, including surgery, radiotherapy, and chemotherapy, is recommended according to stage, performance status, pulmonary function, complications, and patient preference. First-line chemotherapy for advanced MM involves a combination of cisplatin and pemetrexed as the standard treatment. Although this combination has been proven to prolong survival over cisplatin alone in a phase III trial (12.1 months vs.
Source: Lung Cancer - Category: Cancer & Oncology Authors: Source Type: research

Related Links:

Thoracic surgeon Dr. Marcelo DaSilva came to Orlando, Florida, with a lofty goal. He wants to make Central Florida a destination for patients diagnosed with malignant pleural mesothelioma. DaSilva also has the tools to make that goal a reality, building a mesothelioma specialty program at AdventHealth Orlando. “We want to make this a nationally — and internationally — recognized program,” DaSilva told The Mesothelioma Center at Asbestos.com. “People who come to Orlando will not only see Disney World, but they will see excellence in health care. We can do that here.” DaSilva was named chi...
Source: Asbestos and Mesothelioma News - Category: Environmental Health Authors: Source Type: news
Introduction: Malignant pleural mesothelioma (MPM) is a rare disease with poor prognosis. Previous preclinical studies have shown that activin A is overexpressed in MPM and this overexpression is associated with cancer cachexia and resistance to platinum-based chemotherapy. We evaluated circulating activin levels and its endogenous antagonist follistatin/FSTL3 in thoracic malignancy.Methods: Patients suspected of thoracic malignancy were prospectively recruited prior to either diagnostic or therapeutic surgery. Serum samples were collected from 21 patients with MPM, 59 patients with non-small-cell lung cancer (NSCLC), 22 p...
Source: European Respiratory Journal - Category: Respiratory Medicine Authors: Tags: Pleural and mediastinal malignancies Source Type: research
The goal of the Pacific Mesothelioma Center is to be the most innovative nonprofit research and cancer treatment organization in the world. Its latest fundraising event is a perfect example. As part of the Pacific Heart, Lung &Blood Institute, the Pacific Mesothelioma Center will play a major role in the unMASKing the Cure for Cancer Gala, an innovative fundraising idea once used by Prince Charles more than 20 years ago. The November 21 event, held at the UCLA Luskin Conference Center, includes the auctioning of eclectic masks that were hand-painted by various celebrities, including actors, artists, athletes and musici...
Source: Asbestos and Mesothelioma News - Category: Environmental Health Authors: Source Type: news
Rationale: Small cell carcinoma (SCC) occurs mostly in the lung, and small cell lung cancer accounts for 13% of newly diagnosed lung cancers. Only 2.5% of SCC occurs in extrapulmonary sites, and SCC of pleural origin is especially very uncommon. Patient concerns: An 85-year-old man presenting with progressive dyspnea for more than 7 days. Diagnoses: Computed tomography scan of the chest showed massive pleural effusion and diffuse nodular thickening of the pleura on the right chest. Sonography-guided needle biopsy of the pleural mass was performed and histologic and immunohistochemical findings revealed SCC. Since n...
Source: Medicine - Category: Internal Medicine Tags: Research Article: Clinical Case Report Source Type: research
Doctors at the Swiss Group for Clinical Cancer Research in Zurich, Switzerland, have uncovered a novel, anti-tumor compound that could become a needed second-line treatment for pleural mesothelioma cancer. Their recent multicenter phase II clinical trial conducted in Switzerland and Italy revealed the safety and efficacy of lurbinectedin, a synthetically produced agent that inhibits the growth of mesothelioma cells. “We believe this could represent a new treatment option for pleural mesothelioma,” Dr. Yannis Metaxas, oncologist at Kantonsspital Graubunden outside Zurich, told The Mesothelioma Center at Asbestos...
Source: Asbestos and Mesothelioma News - Category: Environmental Health Authors: Source Type: news
Results from a phase III clinical trial comparing Keytruda (pembrolizumab) to standard chemotherapy shows the immunotherapy drug still has a long way to go as a viable treatment option for malignant pleural mesothelioma. Keytruda did not improve progression-free survival for mesothelioma patients who progressed after first-line chemotherapy. The disappointing results from the PROMISE-meso study were presented at the European Society of Medical Oncology (ESMO) annual meeting last week. It was the first randomized trial comparing progression-free survival between immunotherapy and first-line chemotherapy for mesothelioma p...
Source: Asbestos and Mesothelioma News - Category: Environmental Health Authors: Source Type: news
A mesothelioma patient at West Cancer Center in Memphis, Tennessee, is the first in the country to use NovoTTF-100L, a noninvasive electric therapy treatment, since its approval by the U.S. Food and Drug Administration in May. The FDA’s approval of Novocure’s Tumor Treating Fields device for the treatment of mesothelioma marked the first new FDA-approved treatment option for the rare asbestos-related cancer in more than 15 years. NovoTTF-100L uses a low-voltage electrical field that is distributed with three pads attached to the front and back of a person’s chest. The electrical current is designed to di...
Source: Asbestos and Mesothelioma News - Category: Environmental Health Authors: Source Type: news
AbstractBackgroundTumor Treating Fields (TTFields) are a non-invasive, antimitotic therapy delivered to the tumor via transducer arrays applied to the skin at tumor site. The only TTFields-related adverse event (AE) reported in clinical trials was localized dermatitis beneath the arrays. The safety of TTFields has also been investigated in glioblastoma, non-small-cell lung cancer (NSCLC), mesothelioma, pancreatic and ovarian cancer. This meta-analysis reported AEs in clinical studies with TTFields torso delivery.Methods192 patients from 4 pilot studies were included in the analysis: EF-15 (n  = 41, advanced N...
Source: Annals of Oncology - Category: Cancer & Oncology Source Type: research
Thrombotic thrombocytopenic purpura (TTP) is a rare form of thrombotic microangiopathy, characterized by the classic pentad of haemolytic anemia, thrombocytopenia, fever, renal impairment, and neurological complications. Early identification of TTP is essential for instituting early treatment and improving survival. An extensive variety of drugs, including certain cytotoxic agents, have been reported to be associated with TTP [1].
Source: Lung Cancer - Category: Cancer & Oncology Authors: Source Type: research
The Princess Margaret Cancer Center in Toronto has moved from SMART to SMARTER with the recent launch of its latest clinical trial for pleural mesothelioma patients. SMARTER is the acronym for Surgery for Mesothelioma After Radiation Therapy using Extensive pleural Resection, which also describes the latest clinical trial. The phase I clinical trial is an unconventional approach to treatment of mesothelioma: Find the maximum tolerated dosage of hypofractionated radiation to stimulate the immune system before aggressive surgery. It comes on the heels of the SMART protocol, which stands for Surgery for Mesothelioma After Rad...
Source: Asbestos and Mesothelioma News - Category: Environmental Health Authors: Source Type: news
More News: Alimta | Asbestosis | Cancer | Cancer & Oncology | Cardiovascular & Thoracic Surgery | Chemotherapy | Japan Health | Lung Cancer | Mesothelioma | USA Health